Global Netupitant-Palonosetron FDC Market Forecasted to Grow Steadily at 9.6% CAGR Between 2025 and 2029

 Use Code ONLINE20 to Save 20% On Global Market Reports — Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics

 

 What Is the Forecasted Market Size of the Netupitant-Palonosetron FDC Market by 2029?
 The netupitant-palonosetron fixed dose combination (fdc) market size has grown strongly in recent years. It will grow from $351.07 billion in 2024 to $384.5 billion in 2025 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to increasing adoption of combination antiemetic therapies, growing awareness among oncologists, rising prevalence of cancer cases, increasing clinical evidence supporting efficacy and safety, and increasing access to cancer treatments in emerging markets.
 
 The netupitant-palonosetron fixed dose combination (fdc) market size is expected to see strong growth in the next few years. It will grow to $555.45 billion in 2029 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to growing focus on improving quality of life during chemotherapy, rising trend of home-based chemotherapy treatment, growing demand for patient-friendly antiemetic regimens, rising demand for effective antiemetic therapies, and growing adoption of oral fixed-dose combinations over polypharmacy. Major trends in the forecast period include innovative therapeutic advancements, advanced dual-action formulations, technology-driven formulation enhancements, developing oral-disintegrating dosage forms, and innovation in multiday emesis control.
 
 Get your free report sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=24617&type=smp
  
 What Are the Major Growth Drivers for the Netupitant-Palonosetron FDC Market?
 The increasing prevalence of cancer is expected to propel the growth of the netupitant-palonosetron fixed-dose combination (FDC) market going forward. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The increasing prevalence of cancer is due to lifestyle choices such as poor diet, smoking, physical inactivity, and excessive alcohol consumption. Netupitant-palonosetron fixed-dose combination (FDC) enhances cancer treatment by combining two effective antiemetic agents, preventing both acute and delayed chemotherapy-induced nausea and vomiting. They improve patient comfort and adherence to treatment, supporting better overall care outcomes. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, the number of cancer cases diagnosed in Australia reached 160,570 in 2022, marking an increase of 3,789 cases from 156,781 in 2021. Therefore, the increasing prevalence of cancer is driving the growth of the netupitant-palonosetron fixed-dose combination (FDC) market.
 
 Rising Demand For Oral Drugs Fueling The Growth Of The Market Due To Convenience And Improved Patient Compliance
 
 The rising demand for oral drugs is expected to propel the growth of the netupitant-palonosetron fixed-dose combination (FDC) market going forward. Oral drugs refer to medications that are taken by mouth and absorbed through the digestive system to treat or prevent various health conditions. The rising demand for oral drugs is due to their convenience and ease of administration, allowing patients to self-administer medication without the need for professional assistance. Netupitant-Palonosetron FDC enhances the effectiveness of oral drugs by preventing nausea and vomiting, thereby improving patient compliance and treatment outcomes. For instance, in October 2022, according to the Centers for Disease Control and Prevention, a US-based government administration, the dispensing of oral antivirals rose by 57%, increasing from 643 per 100,000 persons between April 24 and May 21, 2022, to 1,012 per 100,000 persons between July 31 and August 28, 2022. Therefore, the rising demand for oral drugs drives the growth of the netupitant-palonosetron fixed-dose combination (FDC) market.
 
 Which Key Segments Are Included in the Netupitant-Palonosetron FDC Market Analysis?
 The netupitant-palonosetron fdc market covered in this report is segmented — 
 
 1) By Product Type: Netupitant, Palonosetron, Fixed Dose Combination (FDC)
 2) By Route Of Administration: Oral Administration, Intravenous (IV) Administration, Sublingual Administration
 3) By Application: Chemotherapy Induced Nausea And Vomiting (CINV), Postoperative Nausea And Vomiting (PONV), General Nausea Management
 4) By Distribution Channel: Hospitals, Retail Pharmacies, Online Pharmacies, Specialty Clinics
 
 Subsegments:
 1) By Netupitant: Oral Netupitant, Injectable Netupitant
 2) By Palonosetron: Oral Palonosetron, Injectable Palonosetron
 3) By Fixed Dose Combination: Oral Fixed Dose Combination, Intravenou Fixed Dose Combination
 
 What New Market Trends Are Emerging in the Netupitant-Palonosetron FDC Market?
 Major companies operating in the netupitant-palonosetron fixed dose combination (FDC) market are focusing on developing advanced formulation products, such as ready-to-use intravenous formulations, to enhance patient convenience and treatment efficacy. Ready-to-use intravenous formulations are pre-prepared, sterile drug solutions that eliminate the need for dilution or mixing, helping netupitant-palonosetron fixed dose combination (FDC) by simplifying administration and reducing preparation errors. For instance, in June 2024, Helsinn Group, a Switzerland-based pharmaceutical company, launched AKYNZEO (fosnetupitant/palonosetron) injection, a ready-to-use vial made available in the United States. This new formulation is designed to simplify preparation and administration for healthcare providers, enhancing convenience in clinical settings. The injection requires no reconstitution or dilution and can be infused directly from the vial using an integrated hanging strap
 
 Who Are the Leading Market Participants in the Netupitant-Palonosetron FDC Market?
 Major companies operating in the netupitant-palonosetron fdc market are Taiho PharmaceuticalTaiho Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Zhejiang Tiantai Pharmaceutical Co. Ltd., Hikma Pharmaceuticals PLC, Glenmark Pharmaceuticals Limited, Helsinn Group, Heron Therapeutics Inc., Metrochem API Private Limited, Mundipharma Pty Ltd, Guangzhou Tosun Pharmaceutical Co. Ltd., Tesaro Inc., Accord Healthcare Ltd., Century Pharmaceuticals Ltd., Specialised Therapeutics Australia Pty Ltd., Aark Pharmaceuticals Ltd., Chemicea Pharmaceuticals Pvt. Ltd., Teva Pharmaceutical Industries Ltd. 
 
 Get the detailed netupitant-palonosetron fdc market report today
 https://www.thebusinessresearchcompany.com/report/netupitant-palonosetron-fdc-global-market-report
 
 Which Regions Are Driving the Highest Demand in the Netupitant-Palonosetron FDC Market?
 North America was the largest region in the netupitant-palonosetron fixed dose combination (FDC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the netupitant-palonosetron fdc market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company: https://thebusinessresearchcompany.com/ 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 Email: info@tbrc.info 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company